HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Biocon’s arm secures marketing approval for pegfilgrastim biosimilar in Japan
Aug-25-2026

Biocon’s wholly-owned subsidiary -- Biocon Biologics has secured marketing approval for its pegfilgrastim biosimilar from Japan’s Ministry of Health, Labour and Welfare (MHLW).  Pegfilgrastim biosimilar, a biosimilar to Neulasta, is developed and manufactured by Biocon Biologics, parent entity of Biocon Biologics UK PLC, with Global Regulatory Partners Japan serving as the Marketing Authorization Holder on behalf of Biocon Biologics and Biocon Biologics UK PLC. Sandoz K.K. shall exclusively promote, sell, and distribute the Product in Japan.

This approval further strengthens the company’s portfolio of biosimilar products in Japan and reaffirms its commitment to increasing patient access to high-quality and affordable medications globally.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

  RELATED NEWS >>